Skip to Content

Gadavist (gadobutrol) Disease Interactions

There are 3 disease interactions with Gadavist (gadobutrol):

Major

Gadobutrol (Includes Gadavist) ↔ Nephrogenic Systemic Fibrosis

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Gadolinium based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Use of these agents should be avoided in these patients unless the diagnostic information is essential and unavailable with non- contrasted MRIs or other diagnostic modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk of NSF appears to be higher in patients with chronic severe renal disease and patients with acute kidney injury. Patients should be screened for acute renal injury and other conditions that might affect renal function such as age >60 years old, hypertension, and diabetes.

Major

Gadolinium-Based Contrast Agents (Includes Gadavist) ↔ Renal Impairment

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Diabetes Mellitus, Hypertension

Gadolinium-based contrast agents (GBCAs), such as gadobutrol, gadobenate dimeglumine, and gadoterate meglumine increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Gadobenate ion is eliminated predominately via the kidneys. The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or acute kidney injury. It is recommended to avoid the use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other processes. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Consider screening patients for acute kidney injury and other conditions that may reduce renal function and for patients at risk for chronically reduced renal function (e.g., age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a GBCA to enhance the contrast agent's elimination. The usefulness of hemodialysis in the prevention of NSF is unknown.

Moderate

Gadobutrol (Includes Gadavist) ↔ Asthma

Moderate Potential Hazard, Moderate plausibility

Applies to: Asthma, Allergies

Patients with history of bronchial asthma might have an increased risk for a hypersensitivity reaction to gadobutrol. Patients should always be assessed for any history of a reaction to contrast media, asthma or other allergic disorders before the administration of gadobutrol.

Gadavist (gadobutrol) drug Interactions

There are 38 drug interactions with Gadavist (gadobutrol)

Gadavist (gadobutrol) alcohol/food Interactions

There is 1 alcohol/food interaction with Gadavist (gadobutrol)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide